Text Size

Radiation Planning Study for High Grade Brain Tumors

The recruitment status of this study is unknown because the information has not been verified recently.
Verified February 2011 by University of Cincinnati.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
University of Cincinnati
ClinicalTrials.gov Identifier:
NCT01191346
First received: August 25, 2010
Last updated: February 11, 2011
Last verified: February 2011
History of Changes
  Purpose

The purpose of this research study is to see if a higher strength MRI procedure provides better images to use in planning radiation treatments for patients with brain tumors in the future.


Condition Intervention
High Grade Glioma
 Other: 3T MRI

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: 3T Versus 1.5T MR Approaches in Target Definition for Malignant Gliomas: Is There a Significant Difference in Tumor Extent and Radiation Treatment Volume?

Resource links provided by NLM:

MedlinePlus related topics: Brain Cancer Cancer
U.S. FDA Resources

Further study details as provided by University of Cincinnati:

Primary Outcome Measures:
  • Treatment volume [ Time Frame: 1 year average ] [ Designated as safety issue: No ]
    To assess the difference in treatment volume for radiation planning in gliomas as calculated using 1.5T versus 3T magnets


Estimated Enrollment: 25
Study Start Date: June 2010
Estimated Primary Completion Date: June 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
3T MRI
Patients receiving 3T MRI
 Other: 3T MRI
3T MRI in addition to standard 1.5T MRI for treatment planning

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with high grade glioma planning to receive radiation therapy

Criteria

Inclusion Criteria:

  • Histologically confirmed, newly diagnosed Grade III-IV glioma
  • Planning to undergo radiation therapy

Exclusion Criteria:

  • Grade I or II glioma
  • Patients unable to undergo MRI imaging
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01191346

Contacts
Contact: UC Cancer Center 513-584-7698

Locations
United States, Ohio
University of Cincinnati Recruiting
Cincinnati, Ohio, United States, 45219
Sponsors and Collaborators
University of Cincinnati
Investigators
Principal Investigator: Jessica Guarnaschelli, MD University of Cincinnati
  More Information

No publications provided

Responsible Party: University of Cincinnati
ClinicalTrials.gov Identifier: NCT01191346     History of Changes
Other Study ID Numbers: BTC-G1
Study First Received: August 25, 2010
Last Updated: February 11, 2011
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
 Neoplasms by Histologic Type
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue

ClinicalTrials.gov processed this record on June 18, 2013